MedPath

Fosaprepitant

Generic Name
Fosaprepitant
Brand Names
Emend, Focinvez, Ivemend
Drug Type
Small Molecule
Chemical Formula
C23H22F7N4O6P
CAS Number
172673-20-0
Unique Ingredient Identifier
6L8OF9XRDC
Background

Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.

Indication

Fosaprepitant is indicated in adult and pediatric patients ≥6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. It is also indicated for the treatment of delayed nausea and vomiting with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Associated Conditions
Acute Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by moderately emetogenic chemotherapy
Clinical Trials
Related News

FDA Grants Priority Review to Astellas' Zolbetuximab for Gastric and GEJ Adenocarcinoma

• The FDA has granted Priority Review to Astellas' Biologics License Application (BLA) for zolbetuximab, a Claudin 18.2-targeted monoclonal antibody. • Zolbetuximab is intended as a first-line treatment for locally advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. • The BLA is supported by positive results from the Phase 3 SPOTLIGHT and GLOW trials, evaluating zolbetuximab in combination with chemotherapy regimens. • The FDA's target action date is set for January 12, 2024, potentially making zolbetuximab the first Claudin 18.2-targeted therapy available in the US.

Triplet Antiemetic Therapy Shows Promise in Preventing Chemotherapy-Induced Nausea and Vomiting

• A phase II trial evaluated the efficacy and safety of triplet antiemetic therapy (palonosetron, aprepitant, and olanzapine) in breast cancer patients undergoing highly emetogenic chemotherapy (HEC). • The study demonstrated a total control (TC) rate of nausea and vomiting in the overall phase (0-120 hours post-chemotherapy), suggesting the effectiveness of the triplet therapy. • The triplet regimen aims to improve upon standard antiemetic therapies by addressing both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV). • Findings support the potential of this triplet combination to become a valuable option for managing CINV in patients receiving HEC for breast cancer.

Atezolizumab and Durvalumab Combination Therapies Not Cost-Effective for ED-SCLC in Japan

• A cost-effectiveness analysis in Japan reveals that atezolizumab and durvalumab, when combined with chemotherapy, are not cost-effective as first-line treatments for extensive-disease small-cell lung cancer (ED-SCLC). • The incremental cost-effectiveness ratios (ICERs) for atezolizumab and durvalumab combination therapies significantly exceeded the willingness-to-pay threshold of 15 million JPY per quality-adjusted life year (QALY). • Sensitivity analyses suggest that substantial price reductions for atezolizumab and durvalumab would be necessary to achieve cost-effectiveness, but such reductions are unlikely to be feasible. • The findings align with previous studies in the USA and China, indicating consistent economic challenges associated with immune checkpoint inhibitor combination treatments for ED-SCLC.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy